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ObjectiveaaThere have been few long-term studies that have assessed factors influencing treatment discontinuation and long-term out-
come of schizophrenia in Korea. The present study aimed to evaluate factors affecting treatment discontinuation and treatment outcome, 
after 10 years, in patients with schizophrenia.
MethodsaaAmong hospitalized patients between 1997 and 1999, 191 patients were given continuous follow-up service. We examined 
the clinical characteristics and outcome of patients who remained in treatment. Regression analyses were used to find any clinical factors 
affecting treatment discontinuation. 
ResultsaaOne hundred thirty-three patients (71.12%) discontinued the treatment. The treatment retention group contained more female 
patients, paranoid-type patients, patients who had shown self-harming behavior, patients receiving clozapine, and patients with good 
medication compliance. The recovery rate was 25%. However, 42.3% did not have gainful employment. Further, most patients couldn’t 
live independently.
ConclusionaaThe results show the importance of gender, patient behavior, medication, and medication compliance in predicting treat-
ment discontinuation in patients with schizophrenia.  Psychiatry Investig 2011;8:22-29
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INTRODUCTION
Schizophrenia is chronic and disabling mental illness with 
serious physical, social, and economic consequences.
1 Estima-
tes give the annual economic burden of schizophrenia as $22.7 
billion for direct health care costs and $40.0 billion for indi-
rect costs.
2 Therefore, there have been extensive studies of the 
longitudinal course and outcome of schizophrenia. Several 
long-term follow-up studies from 1960 through 1980 have 
provided detailed information on schizophrenia’s course and 
outcome, especially with regard to diagnostic issues, specific 
symptoms, functionality problems, treatments, and important 
prognostic factors. McGlashan reviewed 10 North American 
long-term follow-up studies of schizophrenia and concluded 
schizophrenia is a disabling and chronic illness, although pa-
tients do not necessarily show a progressive decline over time.
3 
Subsequent reviews supported the notion that schizophrenia 
is not a disease with a steady downhill course.
After the 1990s, “atypical” agents, or second-generation an-
tipsychotics (SGAs) gradually replaced “typical,” first-genera-
tion antipsychotics. SGAs gave rise to fewer undesirable side 
effects, such as extrapyramidal symptoms, neuroleptic malig-
nant syndrome, and tardive dyskinesia.
4 However, few studies 
have assessed schizophrenia’s long-term course and outcome 
in the SGA era, 1990-2000.
Schizophrenia’s outcome is known to be highly variable and 
heterogeneous. The disease possesses several well-known out-
come determinants, including illness duration, onset age, gen-
der, family support, service availability, personality, and certain 
genetic factors. The most important of these is treatment dis-
continuation, because it is often associated with negative out-
comes that may include symptom exacerbation, social with-SH Jung et al. 
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drawal, re-hospitalizations, and relapse.
5 Since schizophrenia 
is a chronic disease, patients may require lifelong antipsychotic 
maintenance.
6 However, naturalistic studies show that by the 
6th month of treatment, 33% to 44% of patients have dropped 
out, and, by 1 year, as many as 59% have dropped out.
7-9 In turn, 
discontinuing treatment can lead to serious consequences, 
including dangerous behaviors, worsened prognosis, antipsy-
chotic resistance, and increased health care costs. Several st-
udies of schizophrenic patients reported that dropping out of 
treatment discontinuation to be related to patients’ illness be-
liefs, such as insight and the belief that treatment is benefi-
cial.
9,10 The choice of antipsychotic may also influence discon-
tinuation; several studies have demonstrated that discontinu-
ing treatment is more likely if patients are prescribed typical 
antipsychotics, as compared to atypical antipsychotics.
11-13 Ear-
ly identification of factors predicting treatment discontinua-
tion would allow timely adjustments for better management 
of the treatment plan. This study aimed to examine long-term 
outcomes in schizophrenic patients and evaluate factors effect-
ing the discontinuation of treatment against medical advice.
METHODS
Study design
The patient population consisted of all patients admitted to 
the Psychiatric department of Inha University Hospitals in Sou-
th Korea with a diagnosis of schizophrenia, from Jan 1, 1997, 
to Dec 31, 1999. All patients met the Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth Edition (DSM-IV) cri-
teria for schizophrenia.
The definition of “drop-out” was discontinuing treatment ag-
ainst medical advice, excluding the following from the analysis: 
1) Patients whose clinician decided to discontinue the treat-
ment;
2) Patients transferred to another institution; 
3) Patients who died.
And, the definition of “treatment-retention” was remain-
ing in treatment for 10-years consistently. After drop-out, the 
patient might restart medication and maintain the treatment 
until the time of outcome measurement. If these patients were 
categorized to “treatment-retention” group, there might be con-
founding results. Because the aim of the study was evaluating 
the factors affecting discontinuation, we categorized this pa-
tient to “drop-out” group. We compared “drop-out” group to “tr-
eatment-retention” group.
 
Data analysis
Assessment of clinical aspects
We obtained patients’ clinical information, such as age, gen-
der, occupation, marital status, living arrangement, admission 
duration, previous psychiatric history, number of previous psy-
chiatric hospital admissions, type of schizophrenia, medica-
tion at discharge, and medication at dropout via chart review. 
For patients who remained in treatment, we collected the data 
via chart review and telephone interviews with the patients or 
their families.
Outcome measures
1) We defined treatment discontinuation as not taking the 
medications and denying the hospital against medical advice, 
so being dropped out. 
We calculated survival time (i.e., time to discontinuation) as 
the days from the patient’s discharge date to the date the patient 
was lost to treatment.
2) The medications were categorized into the typical antipsy-
chotics group, atypical antipsychotics group, and clozapine 
group. Patients, their family members, their chart, and clini-
cians provided the information on medication compliance 
(“Good”=the patient stopped the medication for <3 months at 
a time, “Moderate”=the patient stopped the medication for 3 
to 12 months at a time, “Poor”=the patient stopped the medic-
ation for >12 months at a time).
3) We categorized each patient’s occupational status as full-
time, part-time, homemaker, student, or unemployed. Full-
time equaled working regularly and independently, without 
anyone’s assistance, and being paid for it. Part-time was work-
ing irregularly or with assistance from institution(s) or family 
members.
4) We analyzed the course of patients’ schizophrenia in as-
sociation with DSM-IV categorizations: “single episodic”, “epi-
sodic”, “chronic”, and “unspecified”.
5) The measures we used to assess patients’ functional levels 
included the Global Assessment of Functioning (GAF). 
We defined a patient as recovered when s/he had only mild 
or questionable psychotic and negative symptoms; further-
more the patient had to be living independently, have a GAF 
score >59, and be working or studying. Partial recovery con-
sisted of having only mild or questionable psychotic and nega-
tive symptoms and a GAF score of 50-59. Deterioration of fu-
nction equaled a GAF score decrease of >20. Stable was a GAF 
score change of <10, if the change in function was unremarkable.
Statistical analysis
To compare baseline demographic and clinical characteris-
tics of the dropout and retention group, we used statistical tests 
that included independent t-tests for continuous variables (such 
as age) and χ2 tests for categorical variables (such as gender). To 
evaluate the correlation between the variables and treatment 
discontinuation, we did a logistic regression analysis, estimat-24  Psychiatry Investig 2011;8:22-29
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ing time until treatment discontinuation using Kaplan-Meier 
survival curves. We used descriptive statistics (occupation, ma-
rital status, monthly income, living arrangement, change in so-
cioeconomic status, change in diagnosis, development of co-
morbid illness, change in functional level, and course of the schi-
zophrenia) to characterize patients who remained in treatment.
We employed Statistical Package for the Social Sciences ver-
sion 12.0 for Windows for all statistical analyses and consider-
ed only p-values less than 0.05 as statistically significant.
RESULTS
Baseline characteristics of patients: treatment loss
group vs. treatment retention group 
Of the 199 patients, we selected 187 patients. The 10 patients 
were excluded because they moved to another hospital. The 1 
patient who died and 1 patient who followed medical advices 
to quit the treatment were excluded. 
During the treatment, 133 patients (71.12%) dropped out 
and 54 patients (28.87%) remained in treatment. Table 1 sum-
marizes the baseline and clinical characteristics of the schizo-
phrenic patients who discontinued treatment as compared to 
those who remained in treatment. The dropout group contain-
ed more males (64.7%) than females (35.3%), and the difference 
was statistically significant (p=0.006). There were no signifi-
cant differences in age of onset and duration of illness. The 
mean age of patients in this study was 29.7 years, with no sig-
nificant difference between the two groups (29.57 years in 
the dropout group and 29.63 years in the retention group, p= 
0.965). The retention group contained more patients with pa-
ranoid-type schizophrenia (63.0% vs. 42.9%, p=0.034) and 
more patients showing self-harming behaviors (16.7% vs. 5.3%, 
p=0.012). Only 11.1% of the retention group received typical 
antipsychotics, 51.9% received atypical antipsychotics, and 
33.3% received clozapine, as compared to the dropout group 
(26.3%, 53.4%, and 18.0%, respectively; p=0.074). The drop-
out group contained a higher proportion of patients with poor 
medication compliance than the retention group did (26.3% 
vs. 9.3%, p=0.023). Regarding other variables (past psychiat-
ric hospitalization, admission duration, occupational status, ma-
rital status, GAF score, etc.), the differences between groups 
were not statistically significant.
Factors affecting treatment discontinuation against 
medical advice
As shown in Table 2, the following variables significantly 
affected treatment discontinuation. Male patients had a 53.6% 
lower risk of discontinuation than female patients had. Hav-
ing a history of self-harming behavior decreased the risk of dis-
continuation by 81.7% as compared to having no previous his-
tory. Patients diagnosed with paranoid schizophrenia had a 
59.5% lower risk of discontinuation than did those diagnosed 
with other types. Patients taking atypical antipsychotics had 
a lower risk of discontinuation compared to those taking ty-
pical antipsychotics, but the difference was not statistically sig-
nificant (odds ratio 0.368 compared to typical antipsychotics, 
p=0.058). Patients taking clozapine had a significantly lower 
risk of discontinuation than did patients taking typical antipsy-
chotics (odds ratio 0.153, p=0.001). Finally, patients having 
poor medication compliance had a significantly greater risk 
of dropping out than did patients having good medication 
compliance.
Figures 1 and 2 illustrate the Kaplan-Meier survival plots 
for treatment discontinuation and rehospitalization; 71.12% 
of patients discontinued treatment. Median time to discontin-
uation was 332 days. In other words, half of them discontin-
ued treatment within 1 year after discharge. Median time to 
rehospitalization was 433 days.
Characteristics of schizophrenia patients who 
remained in treatment
Out of 187 patients beginning the study, 54 (28.87%) remain-
ed in treatment at the end of the 10-year follow-up. Of the 54 
patients, we excluded 2 who declined to be interviewed or pro-
vide their information. Among these 52 patients, 22 (42.30%) 
were unemployed, 10 (19.23%) were full-time workers, and 
13 (25.0%) were part-time workers. Among the employed pa-
tients, 12 (52.2%) earned more than $866.78 (1,000,000 KRW) 
per month. More patients were single (61.53%) than married 
(36.53%). Most of the patients (94.23%) were living with their 
families. In addition, 69.23% of patients or their families in-
dicated no change in the patient’s socioeconomic status. Only 
5.7% indicated an aggravation in socioeconomic status. Of the 
52 patients, 41 (78.84%) showed a remission of their active psy-
chotic symptoms, but 11 (21.15%) showed active psychotic symp-
toms; 48 (92.3%) displayed the “episodic” form of schizoph-
renia, while 21 (40.38%) had no inter-episode symptoms. A 
scant majority of these patients, 27 (51.92%) reached our de-
fined recovery level. Only 4 patients (7.69%) displayed any de-
terioration of functioning, and 21 patients (40.38%) were sta-
ble. Mean GAF score of patients who remained in treatment 
was 58.37 (Table 3).
DISCUSSION
The results of several long-term studies on outcomes of 
schizophrenia patients, including the Iowa 500 follow-up 
study, the Vermont State Hospital Follow-Up Study, Vaillant’s 
follow-up studies, the Washington International Pilot Study 
of Schizophrenia Follow-Up, and the WHO Study (ISoS), were SH Jung et al. 
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Table 1. Baseline characteristics of patients: treatment dropout group vs. treatment retention group
Treatment dropout group
(N=133)
Treatment retention group
(N=54)
p-value
Sex, N (%) 0.006*
Male 086 (64.7) 23 (42.6)
Female 047 (35.3) 31 (57.4)
Age of onset (mean±SD) 25.10±10.30 25.92±11.03 0.479
Duration of illness (mean±SD) 4.42±5.55 4.35±4.19 0.673
Age on admission (mean±SD) 29.57±10.30 29.63±9.930 0.965
Schizophrenia type, N (%) 0.034*
Paranoid 057 (42.9) 34 (63.0)
Disorganized 08 (6.0) 1 (1.9)
Catatonic 05 (3.8) 0
Residual 09 (6.8) 06 (11.1)
Undifferentiated 054 (40.6) 13 (24.1)
Prior psychiatric hospitalization, N (%) 0.335
No 071 (53.4) 33 (61.1)
Yes 062 (46.6) 21 (38.9)
Number of prior psychiatric hospitalization (mean±SD) 1.135±1.790 0.96±1.61 0.638
Self-harming behavior, N (%) 0.012*
No 126 (94.7) 45 (83.3)
Yes 07 (5.3) 09 (16.7)
Comorbid illness, N (%) 0.784
No 120 (90.2) 48 (88.9)
Yes 13 (9.8) 06 (11.1)
School, N (%) 0.166
<6 years 01 (0.8) 2 (3.7)
6-9 years 13 (9.8) 5 (9.3)
9-12 years 027 (20.3) 07 (13.0)
12-16 years 068 (51.1) 26 (48.1)
16-20 years 023 (17.3) 12 (22.2)
Occupation status, N (%) 0.44
Unemployed 059 (44.4) 31 (57.4)
Full-time 015 (11.3) 07 (13.0)
Part-time 08 (6.0) 3 (5.6)
Homemaker 023 (17.3) 06 (11.1)
Student 028 (21.1) 07 (13.0)
Substance abuse, N (%) 0.916
None 114 (85.7) 45 (83.3)
Nicotine 015 (11.3) 07 (13.0)
Alcohol 04 (3.0) 2 (3.7)
Marital status, N (%) 0.537
Single 085 (63.9) 39 (72.2)
Widowed 05 (3.8) 0
Separated 04 (3.0) 1 (1.9)
Married 038 (28.6) 14 (25.9)26  Psychiatry Investig 2011;8:22-29
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variable and heterogeneous, and there have been few studies 
on the course or outcomes of schizophrenia in Korea since 
the 1990s. Therefore, this study is significant for long-term (over 
10 years) studies in Korea.
The present study shows the long-term outcome for schizo-
phrenia in Korea is not poor. The recovery rate was 25%, and 
the rate including partial recovery was 51.9%. Regarding so-
cioeconomic status, 25% of patients responded theirs had im-
proved, and only 5.7% reported their status had deteriorated. 
However, only a small proportion (19.23%) worked indepen-
dently and regularly; 42.3% of patients did not have gainful 
employment. Furthermore, most patients (94.2%) who show-
ed good outcomes continued to live with their families, not in-
dependently. So, there was difference between recovery rates 
and real-world outcomes. In other words, most patients th-
ought by clinicians to be recovered suffered from dysfunction 
and distress. “Recovery”, in schizophrenia, means not only re-
mission of symptoms but also improvement of functioning. 
The differences between recovery rates and real-world out-
come show a lack of social or functional rehabilitation pro-
grams and institutions for schizophrenia patients in Korea.
Only one patient committed suicide. The suicide rate in this 
study was less than that in other studies. Bromet et al.
3 report-
ed that a significant number (approximately 10%) of schizo-
phrenic patients commit suicide during a ten-year follow-up 
period, and Frederic et al.
14 reported 4.1% of their 3,434 pa-
Table 1. Continued
Treatment dropout group
(N=133)
Treatment retention group
(N=54)
p-value
Type of living on admission, N (%) 0.148
Alone 017 (12.8) 2 (3.7)
With family 115 (86.5) 51 (94.4)
Institution 01 (0.8) 1 (1.9)
Type of antipsychotics, N (%) 0.074
Typical 035 (26.3) 06 (11.1)
Atypical 071 (53.4) 28 (51.9)
Clozapine 024 (18.0) 18 (33.3)
Poly 01 (0.8) 1 (1.9)
None 02 (1.5) 1 (1.9)
Drug compliance, N (%) 0.023*
Poor 035 (26.3) 5 (9.3)
Good 078 (58.6) 42 (77.8)
Moderate 020 (15.0) 07 (13.0)
Duration of admission (mean±SD) 43.15±29.39 51.11±32.90 0.35
GAF on admission (mean±SD) 035.6±12.38 34.16±11.80 0.754
GAF on discharge (mean±SD) 52.47±13.67 53.73±12.48 0.318
*p<0.05. GAF: Global Assessment of Functioning
Table 2. Odds ratio of treatment discontinuation
B S.E. Odds ratio 95% confidence interval p-value
Male -0.768 0.365 0.464 0.227-0.950 0.035*
Paranoid SPR -0.903 0.378 0.405 0.193-0.849 0.016*
Self-harming behavior -1.697 0.653 0.183 0.051-0.659 0.009*
Typical antipsychotics - - Reference - -
Atypical antipsychotics -1.001 0.530 0.368 0.130-1.039 0.058*
Clozapine -1.873 0.599 0.153 0.047-0.496 0.001*
Good compliance - - Reference - -
Moderate compliance -0.001 0.517 3.675 0.363-2.753 0.990*
Poor compliance -1.302 0.563 3.675 01.218-11.088 0.020*
*p<0.05. SPR: schizophreniaSH Jung et al. 
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tients suicided during their 10-year follow-up period. This 
study’s low suicide rate could be due to the small sample size 
compared with other studies examining suicide in schizophre-
nia patients. Further studies of larger sample sizes are required 
to assess the suicide rate of schizophrenia patients in Korea.
Very few patients (7.6%) could be said to fit the DSM-IV ca-
tegory of “single episode”. Most patients (92.3%) experienced 
a recurrence of the psychotic episode, with or without complete 
inter-episode remission. However, we observed a deterioration 
in their functioning in only 7.69% of patients. This finding con-
trasts with the view that schizophrenia takes a deteriorating 
and downhill course.
Clearly, recovery from schizophrenia is likely correlated to 
remaining in treatment. We estimate that 71.2% of patients in 
this study discontinued treatment against medical advice. Am-
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Figure 1. Kaplan-Meier survival plot for time to dropout.
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Figure 2. Kaplan-Meier survival plot for time to rehospitalization.
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Table 3. Characteristics of schizophrenia patients who remained 
in treatment
Characteristics of schizophrenia patients Patients, N (%)
Occupation status
Unemployed 22 (42.30)
Full-time 10 (19.23)
Part-time 13 (25)
Homemaker 06 (11.53)
Student 01 (1.923)
Income/month
None 19 (36.53)
<$866.78 (1,000,000 KRW) 11 (21.15)
<$1300.16 (1,500,000 KRW) 08 (15.38)
<$1733.55 (2,000,000 KRW) 04 (7.69)
Marital status
Single 32 (61.53)
Separated 01 (1.923)
Married 19 (36.53)
Type of living
Alone 03 (5.769)
With Family 49 (94.23)
Socioeconomic status change
Improved 13 (25)
No change 36 (69.23)
Aggravated 03 (5.769)
Remission of active psychotic symptom
No 11 (21.15)
Yes 41 (78.84)
Diagnosis change
No 51 (98.07)
Yes 01 (1.923)
Development of comorbid disease
No 43 (82.69)
Yes 09 (17.30)
Course
Single episode with complete remission 01 (1.923)
Single episode with partial remission 03 (5.769)
Episodic with inter-episode complete remission 21 (40.38)
Episodic with inter-episode no complete remission 27 (51.92)
Chronic 00
Unspecified 00
Functional level
Deterioration 04 (7.692)
Stable 21 (40.38)
Partial recovery 14 (26.92)
Full recovery 13 (25)
GAF score, mean±SD 58.37±10.18
KRW: Korean Won, GAF: Global Assessment of Functioning28  Psychiatry Investig 2011;8:22-29
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ong them, half discontinued treatment within 1 year. many 
previous studies have reported schizophrenia patients’ rates 
of discontinuing treatment. However, the results are diverse 
and heterogeneous. Results of the current analysis are consis-
tent with the recent CATIE schizophrenia study. In the CAT-
IE study, 26% of patients remained in treatment, and patients 
receiving olanzapine experienced a slightly longer time to dis-
continuation.
4 Several factors may significantly affect treat-
ment discontinuation. With regard to treatment discontinua-
tion predictors, Mullins et al.
15 reported that concurrent psy-
chotropic medication use, older age, and male gender were 
associated with a lower risk of discontinuing medication. Per-
kins et al.
9 highlighted the importance of treatment response 
in predicting both discontinuation against medical advice 
and poor adherence to medication. In other studies, substance 
use disorders have been associated with poor treatment ad-
herence.
9,16 In this study, prior self-harming behavior was as-
sociated with a significantly lower risk of discontinuing treat-
ment. This may be because patients who performed self-harm-
ing behaviors may be more likely to need, and therefore seek, 
help from clinicians. Alternatively, clinicians and the patient’s 
family may be more anxious and determined to help them 
than in the case of patients who did not perform self-harm-
ing behaviors. Clinicians need to pay more attention to “qui-
et” or “silent” patients who are not at risk of self-harming. 
Moreover, male gender was associated with a lower rate of 
treatment discontinuation. Researchers recognize that schizo-
phrenia’s prevalence may be higher among men than women.
17 
The reason behind this gender differential in treatment reten-
tion may be the gender difference in the prevalence of schizo-
phrenia. The male gender is associated with a poorer outcome 
and disease course than found in the female gender.
14,15,18 Thus, 
male patients may show more severe symptoms and self-harm-
ing behaviors, and greater hostility, resulting in clinicians or 
the patients’ families paying more attention to their treatment 
maintenance. 
In our study, additionally, past psychiatric history and ex-
periences of hospitalization did not affect the likelihood of 
discontinuing treatment. This is not consistent with past studi-
es. Mullins et al.
15 reported that having no prior psychiatric 
hospitalizations was associated with a lower risk of discon-
tinuing treatment. The difference could be attributed to sev-
eral factors, including differences in study designs, subjects, 
countries, and cultures. The fact that experiences of past psy-
chiatric hospitalization did not increase treatment discontin-
uation is a positive result, but we should consider that the ex-
periences also did not have a beneficial effect on treatment 
maintenance.
There were no differences in treatment discontinuation be-
tween the patients who received typical antipsychotics and 
those who received atypical antipsychotics. Only patients 
who received clozapine showed a lower discontinuation rate. 
There have been many studies on the therapeutic differences 
between the typical and atypical antipsychotics. Some found 
evidence of atypical antipsychotics’ superiority, whereas oth-
ers showed the two groups of drugs were generally equivalent 
in terms of efficacy.
19,20 In addition, atypical antipsychotics 
show no advantage over typical antipsychotics regarding quali-
ty of life.
21-23 Furthermore, the results of this study suggest aty-
pical antipsychotics are not superior to typical antipsychotics 
in terms of treatment maintenance.
In our study, having poor (vs. good) compliance resulted in 
a higher probability of discontinuing treatment. This is con-
sistent with past studies. Medication compliance is most im-
portant for remission of symptoms and recovery. Poor medi-
cation compliance is associated with poor treatment response 
and treatment discontinuation.
9 There are several factors that 
predict medication noncompliance, including depressive 
symptoms, poor illness and treatment insight, substance ab-
use or dependence, higher cognitive functioning, and reach-
ing remission status. 
This study had some limitations. First, our study was natu-
ralistic and observational, reflecting treatment in real-world 
settings, where patient control and monitoring may be less 
than found in a randomized, controlled trial. This might bias 
the results toward more optimistic findings. Second, our out-
comes were measured cross-sectionally at a point after more 
than 10-year treatment. So, the outcomes may not reflect the 
patient’s function appropriately. (i.e., the patient’s function 
may be higher than the outcome) Third, we collected the data 
from patients and their families via telephone interviews, not 
face-to-face interviews. Fourth, the clinician’s subjective judg-
ment assessed each patient’s medication compliance. Fifth, we 
investigated the outcome in patients with limited condition 
(i.e., patients who had been treated in the same university hos-
pital for more than ten years). So, the patients may have poor 
course or have some significant residual symptoms in spite of 
long term maintenance treatment. And, these results’ gener-
alizability may be limited, as the data from one institution may 
not be representative for other clinical settings. 
However, there has been little known about the long-term 
course and outcome of schizophrenia patients in Korea since 
the 1990s. Therefore, our results may become the basis for fu-
ture studies. Future research with randomized clinical trials 
and large sample sizes is needed to evaluate the long-term 
course and outcome of patients with schizophrenia in Korea. 
We examined the 10-year long-term outcome for schizo-
phrenia patients in Korea. The recovery rate among these pa-
tients was 25%, and the rate increased to 51% if we included 
the patients showing partial recovery. However, most patients SH Jung et al. 
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were unemployed and unable to take control of their lives in-
dependently. Clinicians need to consider appropriate interven-
tions to improve “social” and “functional” real-world outcomes.
The estimated treatment discontinuation rate was 71.2%, 
and median time to discontinuing treatment was 332 days, 
and to rehospitalization, 433 days. The lower discontinuation 
rates were associated with male gender, self-harming behav-
ior, paranoid type of schizophrenia, clozapine use, and good 
medication compliance.
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